Johnson & Johnson (JNJ)

Johnson & Johnson's stock experienced several notable events in the past six months. The company announced strong performance in Q3 2025 and raised its full-year sales outlook. Johnson & Johnson discussed its preliminary outlook for 2026, indicating expectations for top-line growth of over 5% and similar EPS growth. The company reported Q4 2025 revenue of $24.6 billion, exceeding analyst expectations, and provided optimistic expectations for 2026, forecasting approximately $100.5 billion in revenue. Over the past 12 months, JNJ's stock price increased. The company's Q1 2026 earnings release is scheduled for April 14, 2026.

Johnson & Johnson actively analyzes demand seasonality for its products and services, employing demand planning functions to predict customer needs, improve forecast accuracy, and optimize manufacturing operations. The company utilizes sophisticated tools and processes for seasonality analysis, but specific public details regarding the seasonal patterns of its current Innovative Medicine and MedTech product portfolios are not extensively disclosed. Demand might be influenced by factors such as disease prevalence, healthcare budgets, and medical conference cycles.

Johnson & Johnson is a global healthcare company operating in the pharmaceutical and medical technology industries, focusing on Innovative Medicine and MedTech segments after the spin-off of Kenvue in 2023. The Innovative Medicine segment develops pharmaceutical products across therapeutic areas like oncology and immunology. The MedTech segment offers medical technologies and solutions in surgery, orthopedics, and vision care.

Johnson & Johnson has a significant global presence, operating in over 60 countries and maintaining a market presence in almost every country worldwide. The company has innovation hubs in regions like Boston, London, South San Francisco, and Shanghai. In the United States, Johnson & Johnson has a substantial footprint, with a notable investment in Pennsylvania.

Johnson & Johnson has maintained a strong positive brand reputation, being recognized on Fortune's World's Most Admired Companies list for 23 consecutive years in 2025 and for the 24th consecutive year in 2026. However, the company's reputation has also been significantly impacted by various legal and ethical challenges over the years, including lawsuits related to talcum powder, Risperdal, the opioid crisis, and transvaginal mesh. A July 2023 report by Brand Finance noted a drop in Johnson & Johnson's brand value, though the company still maintained its position as the top pharma brand.

Johnson & Johnson's ownership is predominantly held by institutional investors, who control approximately 73-74% of the company's shares. Major institutional owners include The Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual and public investors also hold a substantial portion of the company's stock, while insiders hold a very small percentage.